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Available online 30 July 2015AbstractBackground: Despite recent improvements in early detection, progress in surgical techniques, and development of chemoradiation thera-
pies, prognosis of esophageal cancer remains poor. The aim of the present study was to assess whether Glasgow Prognostic Score
(GPS), an inflammation-based prognostic score, has prognostic value independent of conventional clinicopathological criteria in patients
undergoing curative resection for esophageal cancer, even in elderly patients.
Methods: We retrospectively reviewed the database of 141 consecutive patients with histologically verified esophageal squamous cell car-
cinoma who underwent potentially curative surgery in our institute, between January 2006 and December 2014. GPS and neutrophil
lymphocyte ratio (NLR) were calculated.
Results: On multivariate analysis, TNM stage (p < 0.0001) and GPS (p ¼ 0.041) were independently associated with worse prognosis in
overall patients with esophageal cancer.
Multivariate analysis evaluated the prognostic factors in two different patient groups: patients younger than 70 years (non-elderly) and
those aged 70 years or more (elderly).
Multivariate analysis demonstrated that TNM stage (p ¼ 0.0003) was an only independent risk factor for a worse prognosis among non-
elderly group. Meanwhile, multivariate analysis demonstrated that TNM stage (p ¼ 0.001) and GPS (p ¼ 0.043) were the independent risk
factor for a worse prognosis among elderly group.
Conclusion: The present study demonstrated that GPS is associated with prognosis and can be considered as an independent prognostic
marker in patients who underwent esophagectomy. Moreover, the GPS has the advantage of being simple to measure, routinely available
and well standardized. But the present study failed to confirm the NLR as a significant predictor of survival following resection for esoph-
ageal cancer.
 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.
org/licenses/by-nc-nd/4.0/).
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Despite recent improvements in early detection, progress
in surgical techniques, and development of chemoradiation
therapies, prognosis of esophageal cancer remains poor
worldwide. Surgery is the mainstay treatment for esopha-
geal cancer, but an appreciable proportion of patients
with advanced esophageal cancer develop recurrence,thor. Department of Digestive and General Surgery,
aculty of Medicine, 89-1 Enya-cho, Izumo, Shimane
: þ81 853 20 2232; fax: þ81 853 20 2229.
orinorihirahara@yahoo.co.jp (N. Hirahara).
16/j.ejso.2015.07.008
e Authors. Published by Elsevier Ltd. This is an open acc
).even after curative resection. Therefore, accurately predict-
ing the prognosis is needed to improve patient survival and
to provide an appropriate preoperative patient counseling.
Host-related factors including performance status,
weight loss, smoking, and comorbidity, in addition to tumor
pathology, play an important role in cancer outcomes.1
However, the use of weight loss as a prognostic factor re-
mains problematic since it is often not well defined and
subject to bias.2,3 Furthermore, performance status is recog-
nized to be subjective.4
There has been an increasing evidence that the cancer-
associated systemic inflammatory response has a greatess article under the CC BY-NC-ND license (http://creativecommons.org/
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sites.5,6 Recent several studies have indicated that the sys-
temic inflammatory response may be associated with poor
outcome in patients with advanced cancer.7e9 In particular,
the GPS, an inflammation-based prognostic score that in-
cludes only the serum levels of C-reactive protein (CRP)
and albumin, is one of the most useful scoring systems
for prognostication of patients with various advanced can-
cers.10e13 The GPS is simple, convenient and can be calcu-
lated easily at the time of admission. Moreover, recent
reports have demonstrated the utility of NLR, which is
calculated from the neutrophil count divided by the
lymphocyte count.14 NLR is also a measure of systematic
inflammation and an elevated NLR was found to predict
poor survival in breast cancer patients.15
The aim of the present study was to assess whether GPS,
an inflammation-based prognostic score, has prognostic
value independent of conventional clinicopathological
criteria in patients undergoing a potentially curative resec-
tion for esophageal cancer, even in elderly patients.
Patients and methodsPatientsWe retrospectively reviewed the database of 141 consec-
utive patients with histologically verified esophageal squa-
mous cell carcinoma who underwent potentially curative
esophagectomy with R0 resection in our institute, between
January 2006 and December 2014. R0 resection was
defined as a complete resection without microscopic
involvement of margins. Thoracoscopic subtotal esopha-
gectomy with a three-field lymph node dissection was per-
formed in all patients, followed by laparoscopic gastric
surgery with an elevation of gastric conduit to the neck
via the posterior mediastinal pathway or retrosternal
pathway with an end-to-end anastomosis of the cervical
esophagus and gastric conduit. The patient’s clinical char-
acteristics, laboratory data, treatment, and pathological
data were obtained from a retrospective review of the re-
cords. No patients had clinical signs of infection or other
systemic inflammatory conditions preoperatively.
Permission to perform this retrospective study was ob-
tained from the ethical board of our institution.Inflammation-based prognostic scoresLaboratory measurements including the serum levels of
CRP, albumin and total cholesterol, white blood cell
(WBC) count, neutrophil count, and lymphocyte count
were performed on the day of admission. GPS and NLR
were calculated based on these clinical data. The GPS
was constructed as previously described.16 Briefly, patients
with both an elevated C-reactive protein (>1.0 mg/dl) and
hypoalbuminemia (<3.5 g/dl) were allocated a score of 2.
Patients in whom only one of these biochemicalabnormalities was present were allocated a score of 1. Pa-
tients in whom neither of these abnormalities was present
were allocated a score of 0. NLR was defined as the abso-
lute neutrophil count divided by the absolute lymphocyte
count.14 For the purposes of analysis, an NLR of S2.5 is
allocated a score of 1, and <2.5 a score of 0.TNM stageThe pathological classification of the primary tumor, the
degree of lymph node involvement and the presence of or-
gan metastasis were determined according to the TNM
classification system (7th edition of the cancer staging
manual of the American Joint Committee on Cancer17).Statistical analysisMeans and standard deviations were calculated and dif-
ferences were identified using Student’s t test. Differences
between categories were identified using the Chi-square
test. Survival curves were produced using the KaplaneMe-
ier survival method. Two groups were compared with a
two-sided log-rank test. Hazard ratios were calculated and
univariate and multivariate analyses were performed using
Cox proportional hazards regression models. The potential
prognostic factors for esophageal cancer were as follows:
age (<70 vs.S70); gender (male vs. female); albumin con-
centration (<3.5 g/dl vs. S3.5 g/dl), CRP (<1.0 mg/dl vs.
S1.0 mg/dl), pStage (1, 2 vs. 3), tumor size (<3 cm vs.
S3 cm), operation time (<600 min vs. S600 min), intra-
operative blood loss (<500 ml vs. S500 ml), GPS (GPS
0 vs. GPS 1e2), and NLR (0 vs. 1). Medical records
were retrospectively reviewed to examine these factors.
All statistical analyses were performed using IBM SPSS
Statistics version 21 for Windows (IBM Corporation, Ar-
monk, NY, USA), and a p values of less than 0.05 was
considered statistically significant.
ResultsRelationships between GPS and clinicopathological
features in esophageal cancerRelationships between GPS and clinicopathological fea-
tures are shown in Table 1. Significant correlations were
observed between GPS and such factors as neutrophil count
(p ¼ 0.016), albumin concentrations (p < 0.0001), C-reac-
tive protein (p < 0.0001), depth of tumor (p ¼ 0.002), TNM
stage (p ¼ 0.04), and NLR (p ¼ 0.001).Prognostic factors for survival in esophageal cancerThe univariate analysis demonstrated that albumin con-
centrations (p ¼ 0.003), TNM stage (p < 0.0001), tumor
size (p ¼ 0.007), and GPS (p ¼ 0.003) were the significant
risk factor for a worse prognosis (Table 2).
Table 1
Relationships between GPS and clinicopathologic features of all patients.
GPS 0 (n ¼ 109) GPS 1 (n ¼ 23) GPS 2 (n ¼ 9) p value
Age(years) 65.7  8.1 66.3  8.4 66.0  7.2 0.988
Gender 0.620
Male 97 22 8
Female 12 1 1
Neutrophil count (mL) 3380.2  1341.3 4252.5  1874.2 4417.4  1549.3 0.016
Lymphocyte count (mL) 1679.0  573.2 1557.8  707.5 1297.1  879.4 0.054
Albumin (g/dL) 4.1  0.3 3.5  0.5 3.0  0.4 <0.0001
CRP (mg/dL) 0.19  0.14 0.90  1.14 1.91  0.63 <0.0001
Location of tumor 0.204
Ce 3 2 1
Ut 6 1 2
Mt 47 11 4
Lt 43 5 2
Ae 10 4 0
Tumor size (mm) 4.2  2.5 4.9  2.5 4.8  1.5 0.090
Depth of tumor 0.002
T1ae1b 57 4 1
T2 10 1 3
T3 35 13 4
T4ae4b 7 5 1
Lymph node metastasis 0.038
N0 65 8 2
N1 27 11 5
N2 10 1 2
N3 7 3 0
Pathological stage 0.004
1ae1b 52 2 1
2ae2b 23 8 3
3ae3c 34 13 5
Operation time (min) 652.6  162.9 662.0  144.5 700.2  163.5 0.6106
Intraoperative blood loss (mL) 670.1  638.8 737.8  666.9 810.0  505.4 0.4485
NLR 2.16  0.88 3.45  2.70 5.09  4.64 0.001
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GPS (p ¼ 0.041) were independently associated with worse
prognosis (Table 2).Relationships between GPS and clinicopathological
features in non-elderly patientsRelationships between GPS and clinicopathological fea-
tures in non-elderly patients younger than 70-year-old (non-
elderly group) are shown in Table 3. Significant correla-
tions were observed between GPS and such factors asTable 2
Univariate and multivariate analysis to assess the prognostic factor for overall p
Variables Patients (n ¼ 138) Category or characteristics
Age 95/46 (<70/S70)
Gender 127/14 (male/female)
Albumin 27/114 (<3.5/S3.5)
CRP 123/18 (<1.0/S1.0)
pStage 89/52 (1,2/3)
Tumor size 56/85 (<3/S3)
Operation time 47/94 (<600/S600)
Intraoperative blood loss 57/84 (<500/S500)
GPS 109/32 (<0/S1.2)
NLR 92/49 (0/1)neutrophil count (p ¼ 0.009), albumin concentrations
(p ¼ 0.015), C-reactive protein (p < 0.0001), depth of tu-
mor (p ¼ 0.036), TNM stage (p ¼ 0.009), and NLR
(p < 0.0001).Prognostic factors for survival in non-elderly patientsAmong non-elderlies, the univariate analysis demon-
strated that TNM stage (p < 0.0001), tumor size
(p ¼ 0.004), and GPS (p ¼ 0.031) were significant asso-
ciated with worse prognosis. Multivariate analysisatients.
Univariate Multivariate
HR 95%CI p value HR 95%CI p value
1.522 0.803e2.789 0.192
0.724 0.329e1.913 0.483
3.170 1.543e6.123 0.003
1.986 0.856e4.063 0.104
5.679 3.052e11.092 <0.0001 4.957 2.543e10.129 <0.0001
2.408 1.255e4.997 0.007 1.168 0.562e2.576 0.685
0.582 0.320e1.058 0.076
1.187 0.652e2.223 0.579
2.747 1.426e5.087 0.003 2.045 1.032e3.928 0.041
1.164 0.616e2.126 0.631
Table 3
Relationships between GPS and clinicopathologic features of non-elderly patients.
GPS 0 (n ¼ 73) GPS 1 (n ¼ 17) GPS 2 (n ¼ 5) p value
Age(years) 61.4  5.7 62.5  5.4 60.6  4.0 0.721
Gender 0.224
Male 64 17 5
Female 9 0 0
Neutrophil count (mL) 3379.6  1370.8 4620.5  1812.5 3887.8  1598.3 0.009
Lymphocyte count (mL) 1720.9  614.3 1553.6  750.6 874.8  465.8 0.015
Albumin (g/dL) 4.2  0.3 3.6  0.5 2.9  0.5 <0.0001
CRP (mg/dL) 0.17  0.11 1.11  1.25 2.22  0.56 <0.0001
Location of tumor 0.630
Ce 2 2 1
Ut 3 1 0
Mt 34 8 3
Lt 25 4 1
Ae 9 2 0
Tumor size (mm) 4.1  2.7 5.3  2.5 4.3  1.7 0.263
Depth of tumor 0.036
T1ae1b 37 3 0
T2 5 0 1
T3 24 11 3
T4ae4b 7 3 1
Lymph node metastasis 0.269
NO 45 6 2
N1 18 7 3
N2 5 1 0
N3 5 3 0
Pathological stage 0.009
1ae1b 34 2 1
2ae2b 15 5 1
3ae3c 24 10 3
Operation time (min) 648.8  152.7 669.5  161.7 650.4  183.1 0.885
Intraoperative blood loss (mL) 588.4  523.0 918.2  688.6 614.0  454.3 0.087
NLR 2.13  0.88 3.79  2.94 6.72  5.94 <0.0001
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independent risk factor for a worse prognosis (Table 4).Relationships between GPS and clinicopathological
features in elderly patientsRelationships between GPS and clinicopathological fea-
tures in elderly patients 70 years of age or older (elderly
group) are shown in Table 5. Significant differences were
observed regarding such factors as neutrophil count
(p ¼ 0.049), albumin concentrations (p < 0.0001), C-Table 4
Univariate and multivariate analysis to assess the prognostic factor for non-elder
Variables Patients (n ¼ 95) Category or characteristics
Gender 86/9 (male/female)
Albumin 14/81 (<0.3.5/S3.5)
CRP 81/14 (<1.0/S1.0)
pStage 58/37 (1,2/3)
Tumor size 40/55 (<3/S3)
Operation time 33/62 (<600/S600)
Intraoperative blood loss 39/56 (<500/S500)
GPS 73/22 (0/S1.2)
NLR 60/35 (0/1)reactive protein (p ¼ 0.004), location of tumor
(p ¼ 0.036), depth of tumor (p ¼ 0.006), and intraoperative
blood loss (p ¼ 0.035).Prognostic factors for survival in elderly patientsAmong elderlies, the univariate analysis demonstrated
that albumin concentrations (p ¼ 0.010), TNM stage
(p ¼ 0.0005), and GPS (p ¼ 0.019) were significant asso-
ciated with worse prognosis (Table 6).ly patients.
Univariate Multivariate
HR 95%CI p value HR 95%CI p value
0.536 0.206e1.829 0.285
2.424 0.885e5.700 0.081
2.208 0.869e4.963 0.091
5.915 2.690e14.330 <0.0001 4.718 2.000e12.221 0.0003
3.316 1.428e9.016 0.004 1.536 0.586e4.454 0.394
0.489 0.228e1.033 0.061
1.455 0.683e3.283 0.336
2.468 1.091e5.278 0.031 1.762 0.756e3.927 0.183
1.288 0.585e2.721 0.517
Table 5
Relationships between GPS and clinicopathologic features of elderly patients.
GPS 0 (n ¼ 36) GPS 1 (n ¼ 6) GPS 2 (n ¼ 4) p value
Age(years) 74.5  4.1 77.3  4.3 72.8  2.5 0.145
Gender 0.530
Male 33 5 3
Female 3 1 1
Neutrophil count (mL) 3381.4  1298.5 3209.8  1782.6 5079.5  1393.7 0.049
Lymphocyte count (mL) 1594.0  476.1 1569.8  631.7 1825.0  1050.8 0.910
Albumin (g/dL) 4.1  0.3 3.2  0.2 3.2  0.1 <0.0001
CRP (mg/dL) 0.22  0.18 0.29  0.33 1.51  0.52 0.004
Location of tumor 0.036
Ce 1 0 0
Ut 3 0 2
Mt 13 3 1
Lt 18 1 1
Ae 1 2 0
Tumor size (mm) 4.4  2.2 4.1  2.2 5.6  0.9 0.309
Depth of tumor 0.006
T1ae1b 20 1 1
T2 5 1 2
T3 11 2 1
T4ae4b 0 2 0
Lymph node metastasis 0.107
N0 20 2 0
N1 9 4 2
N2 5 0 2
N3 2 0 0
Pathological stage 0.081
1ae1b 18 0 0
2ae2b 8 3 2
3ae3c 10 3 2
Operation time (min) 660.1  183.9 640.5  86.3 762.5  131.5 0.410
Intraoperative blood loss (mL) 835.9  808.9 226.7  319.8 1055.0  511.6 0.035
NLR 2.23  0.90 2.48  1.71 3.06  0.64 0.214
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(p ¼ 0.001) and GPS (p ¼ 0.043) were the independent
risk factor for a worse prognosis.Postoperative overall survival and GPSThere existed significant differences in overall survival
between patients with GPS of 0 and 1 (p ¼ 0.004) and be-
tween patients with GPS of 0 and 2 (p ¼ 0.002), but no sig-
nificant difference was observed between patients with GPS
of 1 and 2 (p ¼ 0.615) (Fig. 1).
Since the number of patients with GPS 1 and 2 was
small, we compared the patients with GPS 0 to those
with GPS 1e2 in non-elderly group and elderly group.
In non-elderly group, there existed significant difference
in overall survival between patients with GPS of 0 and 1e2
(p ¼ 0.014) (Fig. 2a).
In elderly group, there existed significant difference in
overall survival between patients with GPS of 0 and 1e2
(p ¼ 0.003) (Fig. 2b).
Discussion
Esophageal cancer is a disease of the elderly, with peak
incidence occurring in patients in their 70 s, and the elderlypopulation is rapidly increasing in worldwide.18 Early
detection and surgery confers the greatest chance of long-
term survival in patients with esophageal cancer. Despite
improvements in surgical techniques and perioperative
care with reduced perioperative mortality in esophageal
surgery, esophagectomy is still known to be associated
with substantial surgical risks, especially in the elderly.
Therefore, there is a continuing interest in prognostic fac-
tors to permit more accurate patient stratification and which
will improve clinical decision making.
In this study, we examined the prognostic significance of
the GPS and NLR in patients undergoing thoracoscopic
subtotal esophagectomy for esophageal cancer. In addition,
we also evaluated the significance of the GPS in both
elderly and non-elderly esophageal cancer patients.
To date, several clinical factors including clinical stage,
performance status, and pathological findings have been
identified as independent predictors of survival in a variety
of common solid tumors.19 However, despite the use of
high-resolution imaging systems, clinical staging is
frequently inaccurate and performance status is rarely
defined objectively.4,20,21
Generally the development of hypoalbuminemia is often
occurred in elderly population. The progression of hypoal-
buminemia is likely to be a secondary event following
Table 6
Univariate and multivariate analysis to assess the prognostic factor for elderly patients.
Variables Patients (n ¼ 46) Category or characteristics Univariate Multivariate
HR 95%CI p value HR 95%CI p value
Gender 41/5 (male/female) 1.453 0.397e9.373 0.610
Albumin 13/33 (<3.5/S3.5) 4.769 1.486e14.605 0.010
CRP 42/4 (<1.0/S1.0) 3.057 0.162e17.615 0.365
pStage 31/15 (1,2/3) 6.267 2.235e19.130 0.0005 5.898 2.033e18.510 0.001
Tumor size 16/30 (<3/S3) 1.265 0.459e4.018 0.660
Operation time 14/32 (<600/S600) 0.808 0.299e2.277 0.676
Intraoperative blood loss 18/28 (<500/S500) 0.767 0.283e2.162 0.605
GPS 36/10 (<0/S1.2) 4.470 1.314e13.719 0.019 3.805 1.046e12.965 0.043
NLR 32/14 (0/1) 0.965 0.304e2.657 0.947
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matory response.22,23 The GPS may thus reflect both the
presence of ongoing systemic inflammatory response
(CRP) and the progressive nutritional decline (albumin)
of the elderly patients with esophageal cancer.
CRP is a non-specific but sensitive marker of systemic
inflammatory response and elevated CRP value is accepted
as a reliable indicator of prognosis for several cancers.1,24,25
Although it is not fully understood why elevated CRP cor-
relates with poor long-term outcomes in cancer patients,
elevated CRP levels can accelerate angiogenesis based on
increased level of circulating levels of vascular growth fac-
tors and interleukins in cancer patients.6,26 Moreover, a sys-
temic inflammatory response can impair the T-lymphocyticFigure 1. KaplaneMeier survival curves showing the relationship between
GPS levels (GPS ¼ 0: solid line, GPS ¼ 1: dotted line, GPS ¼ 2: dashed
line) and overall survival after esophagectomy in all patients with esoph-
ageal cancer.response to cancer, while the intratumoral T cell infiltration
is a favorable prognostic factor by promoting proliferative
activity and IFN-g secretion.27 Besides, the concomitant
nutritional decline reduces tolerance to treatment toxicities
and compliance in cancer patients. Additionally, elevated
acute-phase response proteins, especially CRP, are associ-
ated with the nutrition status and development of cancer-
related cachexia.
While the GPS was a significant predictor of overall sur-
vival in patients with esophageal cancer in this study, TNM
stage remained a significantly more powerful predictor of
survival since the Hazard Ratio (HR) for TNM stage was
4.957 compared with HR of 2.045 for GPS on multivariate
analysis. Therefore, the results of the present study sug-
gested that the GPS and TNM stage are the significant
and complementary factor predicting the survival in pa-
tients with esophageal cancer. But the survival data in
this study is small sample, the data needs to be interpreted
with caution.
Systemic inflammatory responses are associated with al-
terations in circulating white blood cell distribution with a
neutrophilia and relative lymphopenia.28 On the basis of
ex vivo findings, neutrophils significantly modify the tumor
microenvironment via their production of cytokines and che-
mokines, which influence inflammatory cell recruitment and
activation. Additionally, products secreted from neutrophils,
such as reactive oxygen species and proteinases, have spe-
cific roles in regulating tumor cell proliferation and metas-
tasis.29 The NLR was calculated from the neutrophil count
divided by the lymphocyte count.14 The NLR, a biomarker
of the host systemic inflammatory response, has been shown
to be highly promising in stratifying outcome in large co-
horts of patients with cancers arising from unselected sites,
with a higher pre-treatment ratio associated with a poor
prognosis.30,31 The relationship between a high NLR and
poor prognosis is probably complex and still unclear.
Recently, many studies have shown that a high NLR may
indicate an impaired host immune response to the tumor.32
In this study, NLR did not seem to affect the prognosis,
which may due to retrospective small sample size and short
follow-up duration of the study. However, other components
of the systemic inflammatory response including platelet
Figure 2. KaplaneMeier survival curves showing the relationship between GPS levels (GPS ¼ 0: solid line, GPS ¼ 1e2: dotted line) and overall survival
after esophagectomy in (a) non-elderly patents with esophageal cancer, (b) elderly patients with esophageal cancer.
1314 N. Hirahara et al. / EJSO 41 (2015) 1308e1315counts, albumin and CRP levels are prognostically important
in some studies.33 Further examination will need to be per-
formed to confirm these predicting markers.
Consistent with prior studies of esophageal cancer, the
following factors were also associated with worse overall
survival: older age, male sex, comorbidities, more advanced
tumor stage, and worse tumor differentiation. The prog-
nosis of patients diagnosed with operable esophageal can-
cer, even with active treatment, remains poor. Our study
demonstrated that GPS is associated with prognosis and
can be considered as an independent prognostic marker in
patients who underwent esophagectomy. Moreover, the
GPS has the advantage of being simple to measure,
routinely available and well standardized. But the present
study failed to confirm the NLR as a significant predictor
of survival following resection for esophageal cancer. In
summary, our study showed that preoperative GPS is a sig-
nificant predictor of overall survival in patients with esoph-
ageal cancer and that the GPS is superior to NLR as a
predictive factor for survival. Therefore pre-operative mea-
surement of the GPS may be useful to decide the therapeu-
tic strategy. We should examine pre-operative or post-
operative adjuvant chemotherapy and/or radiotherapy for
patients with poor prognosis identified by GPS score.
There were several potential limitations in our study. The
prognostic analysis was a retrospective, small sample size,
short follow-up periods study in a single institution. Further-
more, we excluded patients who had received adjuvant
chemotherapy and/or radiotherapy, which may have influ-
enced our analysis. Thus, larger prospective studies will
need to be performed to confirm these preliminary results.
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